(Q33791290)

English

Tailored antiplatelet therapy can overcome clopidogrel and aspirin resistance--the BOchum CLopidogrel and Aspirin Plan (BOCLA-Plan) to improve antiplatelet therapy

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

29 July 2017

Tailored antiplatelet therapy can overcome clopidogrel and aspirin resistance--the BOchum CLopidogrel and Aspirin Plan (BOCLA-Plan) to improve antiplatelet therapy (English)

1 reference

Europe PubMed Central

29 July 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Horst Neubauer

1

1 reference

Europe PubMed Central

29 July 2017

Andreas F C Kaiser

2

1 reference

Europe PubMed Central

29 July 2017

Heinz G Endres

3

1 reference

Europe PubMed Central

29 July 2017

Jan C Krüger

4

1 reference

Europe PubMed Central

29 July 2017

Andreas Engelhardt

5

1 reference

Europe PubMed Central

29 July 2017

Sebastian Lask

6

1 reference

Europe PubMed Central

29 July 2017

Fenena Pepinghege

7

1 reference

Europe PubMed Central

29 July 2017

Andreas Kusber

8

1 reference

Europe PubMed Central

29 July 2017

Andreas Mügge

9

1 reference

Europe PubMed Central

29 July 2017

language of work or name

0 references

publication date

12 January 2011

1 reference

Europe PubMed Central

29 July 2017

1 reference

Europe PubMed Central

29 July 2017

9

1 reference

Europe PubMed Central

29 July 2017

3

1 reference

Europe PubMed Central

29 July 2017

https://scigraph.springernature.com/pub.10.1186/1741-7015-9-3

0 references

Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3033359

4 July 2018

Impact of clopidogrel loading dose on clinical outcome in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3033359

4 July 2018

ACCF/AHA clopidogrel clinical alert: approaches to the FDA "boxed warning": a report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents and the American Heart Association endorsed by the Society for Ca

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3033359

4 July 2018

Current strategies in antiplatelet therapy--does identification of risk and adjustment of therapy contribute to more effective, personalized medicine in cardiovascular disease?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3033359

4 July 2018

Clopidogrel non-responsiveness and risk of cardiovascular morbidity. An updated meta-analysis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3033359

4 July 2018

Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3033359

4 July 2018

Ticagrelor versus clopidogrel in patients with acute coronary syndromes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3033359

4 July 2018

Assessment, mechanisms, and clinical implication of variability in platelet response to aspirin and clopidogrel therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3033359

4 July 2018

Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Wo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3033359

4 July 2018

Cytochrome p-450 polymorphisms and response to clopidogrel

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3033359

4 July 2018

Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3033359

4 July 2018

Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3033359

4 July 2018

The Residual Platelet Aggregation after Deployment of Intracoronary Stent (PREDICT) score.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3033359

4 July 2018

Poor responsiveness to clopidogrel: drug-specific or class-effect mechanism? Evidence from a clopidogrel-to-ticlopidine crossover study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3033359

4 July 2018

Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3033359

4 July 2018

Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3033359

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3033359

4 July 2018

Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3033359

4 July 2018

Resistance to aspirin in patients after coronary artery bypass grafting is transient: impact on the monitoring of aspirin antiplatelet therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3033359

4 July 2018

Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-9-3

21 January 2018

Dose comparisons of clopidogrel and aspirin in acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-9-3

21 January 2018

Prasugrel versus clopidogrel in patients with acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-9-3

21 January 2018

Dual antiplatelet drug resistance is a risk factor for cardiovascular events after percutaneous coronary intervention

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-9-3

21 January 2018

Comparison of methods for monitoring residual platelet reactivity after clopidogrel by point-of-care tests on whole blood in high-risk patients.

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-9-3

21 January 2018

Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-9-3

21 January 2018

Dose effect of clopidogrel reloading in patients already on 75-mg maintenance dose: the Reload with Clopidogrel Before Coronary Angioplasty in Subjects Treated Long Term with Dual Antiplatelet Therapy (RELOAD) study

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-9-3

21 January 2018

Evaluation of individualized clopidogrel therapy after drug-eluting stent implantation in patients with high residual platelet reactivity: design and rationale of the GRAVITAS trial

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-9-3

21 January 2018

Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents.

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-9-3

21 January 2018

Clinical management of clopidogrel inefficiency by point of care platelet function testing and individual adjustment of anti-platelet therapy--initial experiences

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-9-3

21 January 2018

Predictors of heightened platelet reactivity despite dual-antiplatelet therapy in patients undergoing percutaneous coronary intervention.

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-9-3

21 January 2018

Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-9-3

21 January 2018

The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme. Rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-9-3

21 January 2018

ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention—Summary Article

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-9-3

21 January 2018

How to optimise clopidogrel therapy? Reducing the low-response incidence by aggregometry-guided therapy modification.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3033359

30 October 2018

Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects

1 reference

https://pubmed.ncbi.nlm.nih.gov/21226927

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study

1 reference

https://pubmed.ncbi.nlm.nih.gov/21226927

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days

1 reference

https://pubmed.ncbi.nlm.nih.gov/21226927

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

RANDOMISED TRIAL OF INTRAVENOUS STREPTOKINASE, ORAL ASPIRIN, BOTH, OR NEITHER AMONG 17 187 CASES OF SUSPECTED ACUTE MYOCARDIAL INFARCTION: ISIS-2

1 reference

https://pubmed.ncbi.nlm.nih.gov/21226927

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1741-7015-9-3

1 reference

Europe PubMed Central

29 July 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

29 July 2017

1 reference

Europe PubMed Central

29 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33791290&oldid=1984433501"